Hypersomnia Treatment Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Hypersomnia Treatment Market covers pharmacological and non-pharmacological interventions targeting disorders defined by persistent and excessive daytime sleepiness, most notably narcolepsy with or without cataplexy, idiopathic hypersomnia, and hypersomnia associated with other medical conditions. The global market was valued at approximately $3.54 billion in 2025 and is expected to reach roughly $5.1 billion by 2035. Wakefulness-promoting agents such as modafinil and armodafinil, along with sodium oxybate formulations, currently represent the backbone of available treatments, though new therapeutic classes are in development.

• •Key treated conditions include narcolepsy, idiopathic hypersomnia, and hypersomnia secondary to medical or psychiatric disorders.
• •Primary treatment categories span stimulants, wakefulness-promoting agents, sodium oxybate, and behavioral interventions.
• •Rising clinical recognition and improved diagnostic protocols are expanding the addressable patient population.

Several converging forces are supporting steady market expansion over the coming decade. Increasing prevalence of sleep disorders, fueled by sedentary lifestyles, elevated stress levels, and the growing burden of neurological and psychiatric conditions, is expanding the pool of diagnosed patients. Advances in sleep medicine and the development of novel orexin receptor antagonists and other targeted therapies are broadening treatment options beyond legacy stimulant drugs. Favorable regulatory pathways for orphan disease therapies also support investment in this space.

• •Growing prevalence of sleep disorders, rising healthcare spending, and expanding diagnostic capabilities are key demand drivers.
• •The broader sleep disorder treatment market in the United States alone is estimated at over $6.28 billion in 2025 and projected to reach $16.64 billion by 2035, indicating strong sector momentum.
• •Increased public and clinical awareness of hypersomnia as a serious medical condition is reducing under-diagnosis rates.

The market is typically segmented by disorder type, narcolepsy (with or without cataplexy), idiopathic hypersomnia, and other hypersomnia disorders, as well as by treatment modality, including prescription drugs, diagnostic services, and adjunctive behavioral therapies. North America commands the largest regional share, attributed to high diagnosis rates, advanced healthcare infrastructure, and established reimbursement frameworks. Europe and the Asia-Pacific region represent growing opportunities as awareness and healthcare access improve in those markets.

• •Narcolepsy treatment accounts for the largest segment, driven by higher diagnostic awareness relative to other hypersomnia disorders.
• •North America leads the market, with Europe and Asia-Pacific emerging as high-growth regions.
• •The global mental health market, valued at approximately $410 billion in 2023, provides a broader context of rising investment in neurological and psychiatric treatments.

What are the recent trends and outlook?

Looking ahead, the market is expected to benefit from continued pipeline activity, with several orexin receptor antagonists and novel agents targeting the biological roots of excessive sleepiness in late-stage development. Digital health tools, including sleep-tracking applications and wearable-based monitoring, are beginning to integrate with clinical care pathways and may augment traditional pharmaceutical approaches. The market's growth trajectory through 2035 will likely reflect the combined effect of improved diagnosis, pipeline maturation, and gradual expansion of access in emerging healthcare markets.

• •Pipeline development of orexin receptor antagonists and next-generation wakefulness-promoting therapies could reshape the competitive landscape.
• •Digital health solutions, including sleep-tracking software and apps, are increasingly integrated into the broader sleep-disorder ecosystem.
• •Long-term market growth is supported by demographic trends, ongoing clinical research, and expanding insurance coverage for sleep-disorder treatments.